10-Q · May 5, 2026
Disc Medicine reported a significant net loss of $63.5 million for Q1 2026, highlighting a continued upward trend in operating losses compared to the previous year. The company ended the quarter with a strong cash…
Earnings analysis · 10-Q
IRON earnings analysis
Filed November 5, 2026 · Our reading of the company's report
The latest report
Disc Medicine remains a development-stage biotechnology company with no disclosed revenue or free cash flow and a nine-month net loss of $182.6 million, although Q3 diluted EPS improved to $(1.53) from $(1.77) year over…
Read full summary
Disc Medicine remains a development-stage biotechnology company with no disclosed revenue or free cash flow and a nine-month net loss of $182.6 million, although Q3 diluted EPS improved to $(1.53) from $(1.77) year over year. Liquidity was $682.8 million at September 30, 2026, and management expects funding into 2030, but the new $189.9 million ATM facility introduces additional dilution risk. The key near-term catalyst is resubmission of the bitopertin NDA by the end of 2026, with an anticipated FDA decision by mid-2027; regulatory, financing and clinical-development risks remain significant.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-1.53
What stood out
-
EPS loss improved year over year
Q3 diluted EPS was $(1.53), an improvement from $(1.77) in Q3 2025 and $(1.54) in Q2 2026. The filing does not disclose revenue, gross margin, operating margin or free cash flow in the provided text.
-
Strong liquidity remains
Cash, cash equivalents and marketable securities totaled $682.8 million at September 30, 2026, compared with $791.2 million at December 31, 2025, leaving the company with substantial liquidity despite a $108.4 million decline.
-
Runway extended into 2030
Management expects current liquidity, including net proceeds from the October 2026 underwritten offering, to fund operating and capital expenditure plans and debt service obligations into 2030.
-
Development investment continues
The company reported net losses of $182.6 million for the nine months ended September 30, 2026, compared with $151.7 million for the comparable 2025 period, reflecting continued investment in development programs.
-
Bitopertin regulatory path advancing
The FDA did not approve bitopertin's NDA in February 2026, but management plans to resubmit by the end of 2026 and anticipates an FDA decision by mid-2027 following positive topline APOLLO results.
-
Disclosure controls remain effective
Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2026, and reported no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, those controls during the quarter.
What to watch
-
New ATM creates dilution risk
The company entered into a TD Cowen at-the-market agreement permitting sales of up to approximately $189.9 million of common stock, with commissions of up to 3.0% of gross proceeds. Future use could dilute existing stockholders and pressure the share price.
-
Secured debt and covenant risk
The Hercules Loan Agreement provides for up to $200.0 million of senior secured term loans maturing December 1, 2029, and includes a minimum qualified-cash covenant. A default could accelerate repayment obligations and allow lenders to take control of pledged assets.
-
Foreign-supply and BIOSECURE exposure
The company relies on certain foreign or foreign-owned vendors, while the BIOSECURE Act establishes restrictions on designated biotechnology companies of concern and the initial list is required by December 18, 2026. Tariffs, sanctions or trade restrictions could increase costs or delay clinical-trial materials and services.
-
Persistent losses require capital
The company had an accumulated deficit of $692.8 million as of September 30, 2026 and expects significant and increasing operating losses for the foreseeable future. Additional financing may therefore be required before commercial revenue is generated.
-
Interest-rate sensitivity
The filing states that a 1-percentage-point immediate and uniform increase in interest rates would reduce the net fair value of marketable securities by approximately $3.6 million, although management does not anticipate significant interest-rate exposure.
-
Pipeline remains clinically early
The company reports three product candidates in clinical development, but only one has progressed through a Phase 3 trial to topline results; most programs remain in preclinical or early-to-mid-stage development, increasing clinical execution and regulatory risk.
Management's outlook
No quantitative revenue or EPS guidance was provided. Management plans to resubmit bitopertin's NDA by the end of 2026, anticipates an FDA decision by mid-2027, and believes cash, including October 2026 offering proceeds, will fund operations, capital expenditures and debt service into 2030.
Earlier filings 4
10-K · February 26, 2026
Disc Medicine is a clinical‑stage hematology-focused biotech advancing three clinical programs (bitopertin, DISC-0974, DISC-3405) and preclinical DISC-0998. The company submitted an NDA for bitopertin (accepted Nov…
10-Q · November 6, 2025
Disc Medicine reported a materially wider quarterly loss: net loss of $62,321,000 (net loss per share $1.77) for the three months ended September 30, 2025 versus $26,599,000 (net loss per share $0.89) in the year-ago…
10-Q · August 8, 2024
Disc Medicine reported a Q2 net loss of $26.4M (GAAP net loss per share $1.03) as R&D and G&A increased, while completing a registered direct offering that, together with cash and marketable securities, leaves the…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.